Press release
The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, claims Roots Analysis
London
Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.
Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link - https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Key Market Insights
Over 170 RNAi therapeutics are currently under development
Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage. The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell.
More than 70% of ongoing clinical trials are being conducted in North America and Europe
In total, we came across over 100 clinical trials that have been / are being conducted across the globe. It is worth noting that around 40% of these trials were observed to be phase II studies. Further, 75% of the active clinical trials being conducted in this domain are evaluating siRNAs.
Over 36,000 patents were filed / granted related to RNAi therapeutics since 2014
Majority of these were patent applications (59%), followed by granted patents (40%). It is worth highlighting that both industry and non-industry players are actively involved in this domain. However, majority of the patents related to RNAi therapeutics were filed / granted by industry players (58%).
USD 5.4+ billion invested by both private and public investors, since 2014
Around USD 3 billion was raised through secondary offerings, representing more than 50% of the total capital raised by industry players till July 2019. Further, there have been five instances of debt financing, accounting for more than USD 844 million in financing of RNAi therapeutics related initiatives.
Around 65 partnerships were inked since 2014
Maximum number of deals were reported in 2018. Around 30% of the deals were related to the R&D agreements; this was followed by technology licensing agreements (27%).
RNAi therapeutics market is anticipated to increase at a CAGR of over 45% between 2019-2030
This growth is anticipated to be primarily driven by the target specificity of the drug candidates. North America (primarily the US) are expected to capture the majority share by 2030.
To request a sample copy / brochure of this report, please visit this link - https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Key Questions Answered
Who are the leading industry players in this market?
What are the clinical conditions for which RNAi therapeutics are being developed?
Who are the key investors in the RNAi therapeutics market?
What kind of commercialization strategies are being adopted by RNAi therapeutics developers?
What are the different promotional and reimbursement strategies used for RNAi therapeutics?
What are the prevalent R&D trends related to RNAi therapeutics?
What are the various delivery / technology platforms that are being used for the development of RNAi therapeutics?
What kind of partnership models are used by stakeholders in this industry?
Who are the key service providers in this field of therapeutics?
How is the current and future market opportunity likely to be distributed across key market segments?
The USD 10 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:
Key therapeutic areas
Oncological disorders
Infectious diseases
Genetic disorders
Ophthalmic disorders
Hepatic disorders
Respiratory disorders
Type of RNAi molecule
siRNA
miRNA
shRNA
sshRNA
DNA
Route of administration
Subcutaneous
Intravenous
Intradermal
Intratumoral
Intravitreal
Oral
Intramuscular
Key geographical regions
North America
Europe
Asia Pacific and the Rest of the World
Leading Players
The report features inputs from eminent industry stakeholder(s), according to whom RNAi therapeutics are promising domain of pharmaceutical industry. The report includes detailed transcripts of discussions held with the following expert(s):
Amotz Shemi (Chief Executive Officer, Silenseed)
The research covers brief profiles, featuring an overview of the therapy, current development status and clinical results. Each profile includes information on therapeutic area, indication, targeted gene, route of administration, special designations, mechanism of action, dosage, patent portfolio, technology portfolio, clinical trials and recent developments (if available).
Quark Pharmaceuticals
Alnylam Pharmaceuticals
Dicerna Pharmaceuticals
Souzhou Ribo Life Sciences
Olix Pharmaceuticals
Sirnaomics
Ariz Precision Medicine
Arrowhead Pharmaceuticals
Gradalis
Benitec Biopharma
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Gene Therapy Market (3rd Edition), 2019-2030
2. Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4th Edition), 2019-2030
3. Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, claims Roots Analysis here
News-ID: 2252553 • Views: …
More Releases from Roots Analysis
Autoinjectors Market to Reach USD 299 Billion by 2035 at 5.7% CAGR | SHL Medical …
The global autoinjectors market, valued at USD 170 billion in 2025, will reach USD 181 billion in 2026 and climb to USD 299 billion by 2035, advancing at a CAGR of 5.7% over the forecast period. The growth reflects accelerating demand for self-administration devices across chronic disease management, a wave of biosimilar launches entering autoinjector formats, and a measurable shift in patient care from clinical settings to home environments.
To access…
Antiviral Drugs Market to Reach USD 127 Billion by 2035, Growing at 6.1% CAGR | …
The global antiviral drugs market, valued at USD 69 billion in 2025, will reach USD 74 billion in 2026 and climb to USD 127 billion by 2035, advancing at a CAGR of 6.1% over the forecast period. Infectious disease burden, accelerating R&D pipelines, and the post-pandemic push for novel antivirals are collectively reshaping this market into one of the pharmaceutical sector's most active growth categories.
To explore the complete findings, request…
Antibody Drug Conjugate (ADC) Market to Reach $28.41 Billion by 2035 | AstraZene …
The global antibody drug conjugate (ADC) market, valued at USD 15.29 billion in 2025, will grow to USD 18.69 billion in 2026 and reach USD 28.41 billion by 2035, advancing at a CAGR of 4.8% through the forecast period. With 19 approved therapies already on the market and an active clinical pipeline spanning hundreds of programs, the ADC sector has moved well past proof-of-concept and into a sustained commercial expansion…
Antibody Discovery Services and Platforms Market to Reach $6.3 Billion by 2035 a …
The global antibody discovery market, valued at $2.0 billion in 2025, will climb to $2.2 billion in 2026 and reach $6.3 billion by 2035, compounding at a CAGR of 12.3% over the forecast period. Surging demand for targeted biologics, a record pace of monoclonal antibody approvals, and the accelerating adoption of AI-assisted discovery platforms are converging to make this one of the most commercially consequential segments in the life sciences…
More Releases for RNAi
RNAi Therapeutics Market Shows Promising High-Growth Outlook
The Global RNAi Therapeutics Market 2031 that centers around RNAi Therapeutics Market examines the significant components with a top to bottom methodology and empowers the client to survey the drawn-out based interest additionally predicts explicit executions. This report gives subjective investigation, clarifying item scope and expounding Market experiences and standpoint. The RNAi Therapeutics Market was valued at US$ 1.5 billion in 2021 and is expected to reach US$ 3.2 billion…
RNAi Technology Market to see Booming Business Sentiments
The latest study released on the Global RNAi Technology Market by USD Analytics Research evaluates market size, trend, and forecast to 2030. The RNAi Technology market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Key Players…
RNAi Technology Market to see Booming Business Sentiments
The "Global RNAi Technology" intelligence report, just published by USD Analytics, covers insurers' micro-level study of important market niches, product offers, and sales channels. In order to determine market size, potential, growth trends, and competitive environment, the Global RNAi Technology provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study…
Global RNAi Drug Pipeline Analysis
“Global RNAi Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed based upon RNAi technology. Research report covers all the ongoing drugs being developed in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight for each drug profile in…
Global RNA Interference (RNAi) Therapy Market Outlook 2018
The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry.
Since discovery, RNA interference is considered to be a turning…
Global RNAI Interfering System Market Research Report 2017
Summary
RNAI Interfering System Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
The report firstly introduced the RNAI Interfering System basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes;…
